Supernus Pharmaceuticals SUPN Contingent Consideration Liability (Non-Current)
Contingent Consideration Liability (Non-Current) at other companies
Other financials
Where this comes from
Reported directly by Supernus Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent.
The official record: Supernus Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Supernus Pharmaceuticals's contingent consideration liability (non-current).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Supernus Pharmaceuticals's contingent consideration liability (non-current)?
- Supernus Pharmaceuticals (SUPN) reported contingent consideration liability (non-current) of $206K in Q1 2026.
- How has Supernus Pharmaceuticals's contingent consideration liability (non-current) changed year-over-year?
- Supernus Pharmaceuticals's contingent consideration liability (non-current) decreased by 99.3% year-over-year, from $30M to $206K.
- What is the long-term trend for Supernus Pharmaceuticals's contingent consideration liability (non-current)?
- Over 5 years (2020 to 2025), Supernus Pharmaceuticals's contingent consideration liability (non-current) has grown at a -66.1% compound annual growth rate (CAGR), from $45.8M to $206K.
- What does contingent consideration liability (non-current) mean?
- This represents the estimated fair value of future payment obligations arising from business acquisitions, contingent upon the achievement of specific performance milestones or financial targets. It reflects the long-term financial commitment tied to inorganic growth strategies and the integration of acquired assets. Investors monitor this to evaluate the potential future cash outflows and the success of the company's M&A integration efforts.